Business

CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th

Financial Post · September 15, 2026 at 8:35 a.m.

VANCOUVER, Wash., Sept.

15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced that Robert E.

Hoffman, Chief Financial Officer, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17 th , 2026.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th

More from Financial Post

Flame collected in Turin as Changchun prepares to welcome 2027 Winter Universiade

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

More in Business

Flame collected in Turin as Changchun prepares to welcome 2027 Winter Universiade

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

EasyPark Receives Three Awards at Canadian Parking Association Conference

Hitachi Joins Anthropic’s Critical Infrastructure Defense Program